Results 61 to 70 of about 7,681 (165)

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth

open access: yesHaematologica, 2019
Classic Hodgkin lymphoma tumor cells express a functional CCR5 receptor, and tumor tissues express high CCL5 levels, suggesting that CCL5-CCR5 signaling is involved in tumor-microenvironment formation and tumor growth.
Naike Casagrande   +5 more
doaj   +1 more source

Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients

open access: yes, 2016
International audienceOBJECTIVE: We assessed the virological efficacy of a 6 month maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy combining tenofovir disoproxil fumarate/emtricitabine with maraviroc/raltegravir ...
Lucht, Frédéric   +13 more
core   +1 more source

Chiral (Stereoselective) Drugs, Asymmetric Synthesis, and Racemic Resolution Methods

open access: yesChirality, Volume 38, Issue 7, July 2026.
Chirality is crucial in drug development since both biological targets in the organism and the majority of pharmaceutical compounds are chiral. The synthesis and resolution of chiral compounds are critical steps while developing chiral drugs. Asymmetric synthesis and racemic resolution are the two most common methods for obtaining enantiopure drugs ...
Burcu Karayavuz   +1 more
wiley   +1 more source

Maraviroc for previously treated patients with R5 HIV-1 infection

open access: yes, 2008
Background CC chemokine receptor 5 antagonists are a new class of antiretroviral agents.Methods We conducted two double- blind, placebo- controlled, phase 3 studies - Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment- Experienced ...
Rafael E Campo   +318 more
core   +2 more sources

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens

open access: yesТерапевтический архив, 2013
The paper gives the results of international trials of and guidelines for the use of maraviroc, the first CCR5 receptor antagonist, in treatment regimens for HIV-infected patients.
A V Kravchenko
doaj  

Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents

open access: yeseLife
C-C chemokine receptor type 5 (CCR5) antagonists may improve both acute stroke outcome and long-term recovery. Despite their evaluation in ongoing clinical trials, gaps remain in the evidence supporting their use.
Ayni Sharif   +15 more
doaj   +1 more source

T‐Cell Biology in the Female Reproductive Tract: Relevance to HIV Infection

open access: yesAmerican Journal of Reproductive Immunology, Volume 95, Issue 6, June 2026.
ABSTRACT Worldwide, most HIV infections occur across a mucosal surface during sexual contact, with women accounting for nearly half of reported new HIV infections across the globe in 2024. Most new infections in women and girls are believed to involve transmission across mucosal surfaces of the lower reproductive tract, which includes the vagina and ...
Barbara L. Shacklett   +2 more
wiley   +1 more source

Development and Validation of a Genotypic Assay to Quantify CXCR4- and CCR5-Tropic Human Immunodeficiency Virus Type-1 (HIV-1) Populations and a Comparison to Trofile®

open access: yesViruses
HIV-1 typically infects cells via the CD4 receptor and CCR5 or CXCR4 co-receptors. Maraviroc is a CCR5-specific viral entry inhibitor; knowledge of viral co-receptor specificity is important prior to usage. We developed and validated an economical V3-env
Daisy Ko   +7 more
doaj   +1 more source

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis

open access: yesMalaria Journal, 2011
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported.
Ivanovic Jelena   +8 more
doaj   +1 more source

Prevotella bivia Influences Antiretroviral Pharmacokinetics and Viral Replication in an Ex Vivo Vaginal Tissue Model

open access: yesClinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT The vaginal microbiome plays a complex role in tenofovir's mucosal pharmacology. While the relative contribution of systemic versus local concentrations to PrEP PK/PD is an ongoing debate, the development of effective HIV prevention requires an understanding of events at the site of transmission.
Alyssa M. Lantz   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy